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This study reports that TNF-a is a potent mitogen
for human bone marrow sternal cells in vitro
(assessed by [3H]-thymidine incorporation into
DNA and cell counts). In contrast, cytokines such
as IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-6, LIF, SCF, M-CSF,
G-CSF and GM-CSF had no effect. The effect of
TNF-a on the growth of human bone marrow
stromal cells could be of importance during
in￿ ammatory processes which take place in the
marrow, for example marrow ￿ brosis.
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Introduction
Bone marrow stromal cells (mostly ￿broblast-
like cells) regulate hematopoiesis by producing
cytokines and colony-stimulating factors
(CSFs).1,2 While numerous studies highlight the
effects of stromal cell-derived cytokines on the
growth of human hematopoietic progenitors,3,4
less information is available on the role of
cytokines and CSFs on the growth of marrow
stromal cells. Tumour necrosis factor alpha
(TNF-a) is a pleiotropic cytokine which med-
iates numerous biological responses such as
immunomodulation, in￿ammation and antimi-
crobial defence.5 Among its effects, TNF-a plays
a role in the regulation of myelopoiesis, erythro-
poiesis, lymphopoiesis and thrombocytopoie-
sis.6 since TNF-a is a mitogen for human
dermal, foreskin and lung ￿broblasts,7- 9 we
have investigated its effect on human bone
marrow stromal cell proliferation.
Materials and Methods
This study was performed according to the
Helsinki recommendations. Cultures of human
bone marrow sternal cells were established
from stromal bone marrow samples harvested
from untreated patients referred for diagnosis.
Mononuclear marrow cells were isolated by
separation on a Ficoll gradient (400 3 g
20 min), washed twice with HBSS (400 3 g,
10 min), and seeded in 75 cm2 culture ￿asks
(23 106 cells/ml; 5 3 105 cells/cm2) in RPMI
1640 with 20% FCS (Gibco, Cergy Pontoise,
France), penicillin (100 U/ml) and streptomycin
(100 mg/ml) (culture medium) at 378 C in 5%
CO2 in air as previously described.10 After 1
week, non-adherent cells were removed from
culture ￿asks. Adherent cells were grown to
con￿uence for 3±4 weeks with weekly changes
of medium and were subcultured after trypsin
treatment. Cells were analysed on a Pro￿le
Coulter using Epics Pro￿le Software to deter-
mine the cellular characteristics of the adherent
layers. As previously reported,11 more than
99.8%of cells were CD2- and CD22- indicating
the absence of T and B cells on the layers and
4%of cells were CD14+ and CD33+ indicating a
monocytic lineage.
Cells (13 104/well) were plated for 24 hours
in 96-well plates in 100 ml of culture medium.
Adherent cells were washed with HBSS and
200 ml of serum-free medium was added to each
well for 2 days. Adherent cells were reactivated
with 100 ml of RPMI 1640 with 5% FCS and
stimulated with TNF-a, interleukin-1a (IL-1a),
IL-1b, IL-2 (Tebu, Le Perray en Yvelines, France),
IL-3 (Sandoz, Rueil-Malmaison, France), IL-4
(Shering Plough Co.), IL-6, leukaemia inhibitory
factor (LIF), stem cell factor (SCF) (Tebu),
macrophage-CSF (M-CSF) (Cetus Corporation
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doz), and granulocyte ±macrophage CSF (GM-
CSF) (R & D Systems, Oxon, UK) or the
appropriate vehicle (10 ml RPMI). After 60
hours of incubation, cultures (six replicates per
sample) were pulsed for 12 hours with
1 mCi/ml [3H]-thymidine and the cells were
harvested using a Skatron cell harvester. In
separate sets of experiments, cells (four repli-
cates per sample) were harvested after trypsin
treatment (0.05%trypsin for 5 min at 378 C) and
counted by using a haemocytometer. In some
experiments the effect of TNF-a was investi-
gated with cells reactivated with 20%FCS and
with cells grown in 5%FCS without the step of
serum-deprivation. In other experiments TNF-a
was added 24 hours after reactivation with 5%
FCS.
Results were compared with the Mann±Whit-
ney U-test or Student’s t test for paired samples.
A P, 0·05 was considered signi￿cant.
Results and Discussion
These experiments were done with marrow
stromal cells from 25 different donors. Previous
experiments showed that FCS increased [3H]-
thymidine incorporation by human bone mar-
row stromal cells in a dose-dependent manner
with 5% FCS and 20% FCS as suboptimal and
optimal concentrations, respectively.2
In growth synchronized cells, TNF-a at
1 ng/ml increased DNA synthesis by 230 61%
(Fig. 1). In similar experimental conditions (i.e.,
5%FCS in growth medium), IL-1a, IL-1b, IL-2,
IL-3, IL-4, IL-6, LIF , SCF , G-CSF , GM±CSF (both
from 10 ng/ml to 0·1 ng/ml) and M-CSF (from
1000 Ul/ml to 10 Ul/ml) had no signi￿cant
effect (P. 0·05) on DNA synthesis (data not
shown). The stimulatory effect of TNF-a at
1 ng/ml was found with cells from 15 of 15
different donors but was not observed with
non-synchronized cells (data not shown). In
growth medium with 20% FCS, TNF-a stimu-
lated [3H]-thymidine incorporation by 51 9%
(mean SEM of three experiments). Since the
greatest increase was seen with 5% FCS in
medium, we focused on this concentration for
the remainder of the experiments.
We next assessed whether the observed
stimulation of DNA synthesis was dependent on
the time of TNF-a addition. When TNF-a was
added 24 hours after reactivation with FCS, a
signi￿cant (P , 0·05, four experiments) in-
crease in [3H]-thymidine incorporation was
found in TNF-a-treated cells (2552 506 dpm)
as compared with controls (1552 522 dpm)
indicating that serum-stimulated marrow stro-
mal cells can be further regulated by TNF-a.
[3H]-thymidine uptake is considered a good
index of cell proliferation but may also, in part,
re￿ect intracellular events other than cell divi-
sion such as difusion of DNA precursors.12
Therefore, we assessed the effect of TNF-a on
cell number. As shown in Fig. 1B, a signi￿cant
increase of marrow stromal cell number was
found 3 days after TNF-astimulation.
This study indicates that numerous cytokines
and growth factors, which act positively or
negatively on the growth of human marrow
progenitors, have no effect on the growth of
human marrow stromal cells. Among the 12
molecules tested in this study, only TNF-a is a
potent mitogenic stimulus for their growth. This
FIG. 1. Effects of TNF-a on the growth of human bone marrow stromal cells with 5% FCS in the culture medium. (A) Effects
on [3H]-thymidine incorporation: results (in dpm) are reported as mean SEM from four independent experiments each of
six replicates. Data are compared with the Mann±Whitney U-test. (B) Effects on cell counts: experiments were performed
with cells from ® ve different donors. Data are compared with Student’s t-test for paired data.
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F. Rougier et al.result agrees with the positive effect of TNF-a
on the proliferation of human ￿broblasts of
different origins.7- 9 These results highlight for
the ￿rst time a mechanism which could be of
importance for understanding the increased
population and activity of bone marrow ￿bro-
blasts in marrow ￿brosis associated with several
haematological malignancies.
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